Questcor Pharmaceuticals (Nasdaq: QCOR ) is expected to report Q4 earnings on Feb. 26. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Questcor Pharmaceuticals's revenues will expand 89.4% and EPS will grow 87.5%.
The average estimate for revenue is $143.0 million. On the bottom line, the average EPS estimate is $0.90.
Last quarter, Questcor Pharmaceuticals reported revenue of $140.3 million. GAAP reported sales were much higher than the prior-year quarter's $59.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.91. GAAP EPS of $0.91 for Q3 were 160% higher than the prior-year quarter's $0.35 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 94.7%, 90 basis points better than the prior-year quarter. Operating margin was 60.1%, 390 basis points better than the prior-year quarter. Net margin was 39.7%, 150 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $491.8 million. The average EPS estimate is $3.04.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 467 members out of 530 rating the stock outperform, and 63 members rating it underperform. Among 136 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 107 give Questcor Pharmaceuticals a green thumbs-up, and 29 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Questcor Pharmaceuticals is outperform, with an average price target of $44.89.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Questcor Pharmaceuticals. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.